In addition to an impairment of the GSK3β-directed β-TrCP pathway, aberrant accumulation of Nrf2 is augmented by inhibition of the Keap1-based proteasome-mediated degradation in Nrf1α−/−-derived tumor cells. The gene discussed is BTRC; the disease is neoplasm.